APP and Alzheimer disease: As part of personalized care, detailed family history and even genetic testing for familial AD mutations (APP/PSEN1/PSEN2) may be appropriate in early-onset cases; patients with autosomal-dominant AD mutations will invariably develop amyloid pathology, and trials are ongoing to see whether treating such individuals pre-symptomatically with anti-amyloid antibodies can delay onset.